Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer

NCT02269670 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT02269670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
November 25, 2014
Completion date
January 25, 2021
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-positive breast cancer, her2-negative breast cancer, progesterone receptor-positive breast cancer, recurrent breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer